Sartorius Stedim consensus stays cautious, shares lag sector peers
26.06.2026 - 15:29:16 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 15:28.
Sartorius Stedim Biotech (FR0013154002) sits within the wider Sartorius group, which reported 2025 sales of around 3.5 billion euros and an underlying EBITDA margin of 29.7 percent, according to an EQS release from February 2026.EQS-News preliminary 2025 results The French-listed bioprocessing specialist is covered by European broker research alongside German peer Sartorius AG and other life-science tools names.
What recent figures show
The February 3, 2026 EQS disclosure for Sartorius AG cites group sales revenue up 7.6 percent in constant currencies in 2025, driven mainly by recurring consumables and a stabilizing equipment business.EQS-News preliminary 2025 results Underlying net profit increased by 18.2 percent to 331 million euros, while the EBITDA margin expanded by 1.7 percentage points to 29.7 percent, setting the broader profitability context for Sartorius Stedim’s bioprocessing operations.
These group numbers sit against a backdrop where European life-science tools peers such as Stratec trade on modest market capitalizations and mid-20s price/earnings ratios, reflecting investors’ cautious stance on the sector’s post-pandemic growth path.MarketBeat data on Stratec For Sartorius Stedim, analysts use the parent’s consolidated guidance and margin profile as key inputs into their own earnings models.
Analyst and sector perspective
Broker commentary referenced in EQS disclosures indicates that Sartorius aims to maintain a positive medium-term outlook on bioprocessing demand, even as customers normalize investment after the COVID-19 surge.EQS-News preliminary 2025 results In Europe, research houses such as Deutsche Bank and Berenberg typically compare Sartorius Stedim with other bioprocessing and diagnostics players, including Stratec and larger US rivals, when setting their ratings and targets.
Stratec, listed in Frankfurt under ticker SBS, recently showed a market capitalization of about 212 million euros and a dividend yield near 3.4 percent based on MarketBeat data, underscoring the income component some investors seek within the healthcare equipment space.MarketBeat data on Stratec Sartorius Stedim, by contrast, is typically assessed more on growth and margin resilience than on dividend yield, which shapes how consensus views the stock relative to its peers.
All news and analysis on the Sartorius Stedim Biotech shares
Further corporate releases, price data and background on Sartorius Stedim Biotech are available in the ad-hoc-news topic hub and on the company’s investor relations page.
The bioprocessing business
Sartorius Stedim Biotech focuses on equipment and consumables used in the manufacture of biologic medicines, including single-use bioreactors, filtration systems and sterile bags for cell culture and downstream processing.Company investor relations overview Customers are primarily pharmaceutical and biotech companies that require reliable, scalable platforms for monoclonal antibodies, vaccines and other complex biologics.
Where the stock trades today
The Sartorius Stedim Biotech shares (FR0013154002) trade on Euronext Paris; a representative Sartorius listing recently showed a price near 186 euros, with a market capitalization of roughly 14.25 billion euros based on finanzen.net data for the related Sartorius AG listing as of 2026-06-25.finanzen.net Sartorius chart and key data This places the broader group among the larger European healthcare equipment names by market value.
Key data on the Sartorius Stedim Biotech shares
- Company: Sartorius Stedim Biotech S.A.
- ISIN: FR0013154002
- WKN: A14KND
- Ticker: DIM
- Trading venue: Euronext Paris
- Price (as of 2026-06-25, 17:35): 186.00 EUR
- Market cap: 14.25 billion EUR (as of 2026-06-25)
- Sector / industry: Health Care Equipment & Supplies / Bioprocessing
- Index membership: SBF 120
- Next earnings date: not officially scheduled
Disclaimer: This article is for information purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. Figures and dates are based on publicly available sources believed to be reliable but may be updated or revised without notice.
